Genetic Modifiers of Immune Evasion by Cytomegalovirus in Glioblastoma

胶质母细胞瘤中巨细胞病毒免疫逃避的基因修饰

基本信息

  • 批准号:
    8465930
  • 负责人:
  • 金额:
    $ 17.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-01 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Increasing evidence implicates human cytomegalovirus (HCMV) in the etiology of glioblastoma (GBM): HCMV proteins have been implicated as tumor promoters in gliomagenesis; glioma grade-as well as patient survival-directly correlates with the level of HCMV gene products. In this proposal, we seek to understand why this common herpesvirus causes disease in only a subset of those infected: HCMV seroprevalence, 80% vs. the prevalence of GBM, 0.025%. HCMV has evolved highly sophisticated immune evasion strategies. One strategy involves generating two proteins-encoded by genes TRL11/IRL11 and UL119-UL118-that have functional properties of the Fc?R, which may enable the virus to evade host immunosurveillance by evading the effector consequences of antibody binding, such as ADCC. Recent studies from our laboratory show that alleles of a major gene complex of the immune system-GM allotypes encoded by three highly polymorphic IGHG loci on chromosome 14-modulate this viral strategy: The HCMV TRL11/IRL11-encoded Fc?R has significantly higher affinity for IgG1 proteins expressing the GM 3+,1-,2- allotypes than for those expressing the allelic GM 17+,1+,2+ allotypes (p = 0.0005). These observations led us to hypothesize that GM genes are effect modifiers of HCMV-GBM association and the underlying mechanisms include their contribution to anti-HCMV antibody responses and their modulating influence on the viral immune-evasion strategies. The following specific aims will test our hypothesis: 1) Determine if the distribution of GM determinants in GBM patients is different from that in controls. DNA from GBM patients and controls will be genotyped for several GM alleles. Because of their higher affinity to the HCMV-encoded Fc?R, anti-HCMV IgG1 antibodies expressing the GM 3+,1-,2- allotypes would be more likely to have their Fc domains scavenged, thereby reducing their immunological competence to eliminate the virus through ADCC and other Fc-mediated effector mechanisms. Consequently, the frequency of these allotypes would be expected to be higher in patients than in controls; 2) Compare the levels of anti-HCMV antibodies in GBM patients and in controls, and determine if they are associated with particular GM alleles. Antibodies to HCMV glycoprotein B (gB) in the sera/plasma of patients and controls will be quantitated by an ELISA and the levels will be compared between the two groups. We will also determine whether the antibody levels are associated with particular GM alleles; 3) Determine if HCMV-encoded Fc?R proteins bind differentially with genetically disparate Fc (GM) regions of anti-HCMV IgG antibodies in GBM patients. Ectodomains of HCMV-encoded Fc?Rs will be cloned and expressed. We will purify IgG antibodies directed against HCMV gB from the sera of GBM patients. Binding and comparative affinities of IgG molecules of different GM allotypes to the HCMV Fc?Rs will be monitored by surface plasmon resonance. Results from the proposed investigation are likely to open a new avenue of investigation in a malignancy that kills approximately 13000 people every year in the U.S. alone.
描述(由申请人提供):越来越多的证据表明人巨细胞病毒(HCMV)与胶质母细胞瘤(GBM)的病因有关:HCMV蛋白在胶质瘤形成中作为肿瘤启动子;胶质瘤分级——以及患者生存——与HCMV基因产物的水平直接相关。在本提案中,我们试图理解为什么这种常见的疱疹病毒仅在一部分感染者中引起疾病:HCMV血清阳性率为80%,而GBM的患病率为0.025%。HCMV已经进化出高度复杂的免疫逃避策略。一种策略涉及产生两种蛋白质-由基因TRL11/IRL11和ul119 - ul118编码-具有Fc?R,这可能使病毒通过逃避抗体结合的效应后果(如ADCC)来逃避宿主免疫监视。我们实验室最近的研究表明,免疫系统的一个主要基因复合体的等位基因(由14号染色体上三个高度多态性的IGHG基因座编码的gm同种异体)调节了这种病毒策略。R对表达GM 3+、1+、2-等位基因的IgG1蛋白的亲和性显著高于表达GM 17+、1+、2+等位基因的IgG1蛋白(p = 0.0005)。这些观察结果使我们假设转基因基因是HCMV-GBM关联的效应调节剂,其潜在机制包括它们对抗hcmv抗体反应的贡献以及它们对病毒免疫逃避策略的调节作用。以下具体目标将检验我们的假设:1)确定GBM患者中GM决定因子的分布是否与对照组不同。将对GBM患者和对照组的DNA进行几种转基因等位基因的基因分型。因为它们对hcmv编码的Fc?R,表达GM 3+,1-,2-同种异体的抗hcmv IgG1抗体更有可能被Fc结构域清除,从而降低其通过ADCC和其他Fc介导的效应机制消除病毒的免疫能力。因此,这些同种异体的频率预计在患者中高于对照组;2)比较GBM患者和对照组的抗hcmv抗体水平,确定它们是否与特定的GM等位基因相关。采用ELISA定量检测患者和对照组血清/血浆中HCMV糖蛋白B (gB)抗体,并比较两组之间的水平。我们还将确定抗体水平是否与特定的转基因等位基因相关;3)确定是否hcmv编码Fc?在GBM患者中,R蛋白与抗hcmv IgG抗体基因不同的Fc (GM)区域结合的差异。hcmv编码Fc?Rs将被克隆和表达。我们将从GBM患者的血清中纯化针对HCMV gB的IgG抗体。不同GM异型IgG分子与HCMV Fc的结合及比较亲和力Rs将由表面等离子体共振监测。拟议的调查结果可能会为恶性肿瘤的调查开辟一条新的途径,每年仅在美国就有大约13000人死亡。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JANARDAN P PANDEY其他文献

JANARDAN P PANDEY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JANARDAN P PANDEY', 18)}}的其他基金

Immunoglobulin Genes and Immunity to HSV1 in Alzheimer's Disease
阿尔茨海默病中的免疫球蛋白基因和 HSV1 免疫
  • 批准号:
    10576613
  • 财政年份:
    2023
  • 资助金额:
    $ 17.79万
  • 项目类别:
IGHG Genes (GM Allotypes) and Anti-CMV (UL70) Antibody Responses as Prognostic Markers for Chronic Graft-Versus-Host-Disease
IGHG 基因(GM 同种型)和抗 CMV (UL70) 抗体反应作为慢性移植物抗宿主病的预后标志物
  • 批准号:
    10624498
  • 财政年份:
    2023
  • 资助金额:
    $ 17.79万
  • 项目类别:
FCGRIIIA and IGHG (GM) Genotypes and Immunity to HSV1 in Herpes Stromal Keratitis
疱疹性基质性角膜炎中的 FCGRIIIA 和 IGHG (GM) 基因型以及对 HSV1 的免疫
  • 批准号:
    10675575
  • 财政年份:
    2022
  • 资助金额:
    $ 17.79万
  • 项目类别:
FCGRIIIA and IGHG (GM) Genotypes and Immunity to HSV1 in Herpes Stromal Keratitis
疱疹性基质性角膜炎中的 FCGRIIIA 和 IGHG (GM) 基因型以及对 HSV1 的免疫
  • 批准号:
    10507311
  • 财政年份:
    2022
  • 资助金额:
    $ 17.79万
  • 项目类别:
Immunoglobulin GM (γ marker) Allotypes and Immunity to HSV1 in Alzheimer’s Disease
阿尔茨海默病中免疫球蛋白 GM(γ 标记)同种异型和对 HSV1 的免疫
  • 批准号:
    10464940
  • 财政年份:
    2021
  • 资助金额:
    $ 17.79万
  • 项目类别:
Genetic Markers of IgG and Cytomegalovirus Immunoevasion in Alzheimer Disease
阿尔茨海默病中 IgG 和巨细胞病毒免疫逃避的遗传标记
  • 批准号:
    9386264
  • 财政年份:
    2017
  • 资助金额:
    $ 17.79万
  • 项目类别:
Genetic Modifiers of Immune Evasion by Cytomegalovirus in Glioblastoma
胶质母细胞瘤中巨细胞病毒免疫逃避的基因修饰
  • 批准号:
    8374071
  • 财政年份:
    2012
  • 资助金额:
    $ 17.79万
  • 项目类别:
Immunoglobulin Allotypes in Hepatitis C Virus Infection
丙型肝炎病毒感染中的免疫球蛋白同种异型
  • 批准号:
    7029163
  • 财政年份:
    2006
  • 资助金额:
    $ 17.79万
  • 项目类别:
Immunoglobulin Allotypes in Hepatitis C Virus Infection
丙型肝炎病毒感染中的免疫球蛋白同种异型
  • 批准号:
    7367031
  • 财政年份:
    2006
  • 资助金额:
    $ 17.79万
  • 项目类别:
Immunoglobulin Allotypes in Hepatitis C Virus Infection
丙型肝炎病毒感染中的免疫球蛋白同种异型
  • 批准号:
    7188051
  • 财政年份:
    2006
  • 资助金额:
    $ 17.79万
  • 项目类别:

相似海外基金

Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10506915
  • 财政年份:
    2021
  • 资助金额:
    $ 17.79万
  • 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10325006
  • 财政年份:
    2021
  • 资助金额:
    $ 17.79万
  • 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
  • 批准号:
    1746198
  • 财政年份:
    2018
  • 资助金额:
    $ 17.79万
  • 项目类别:
    Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
  • 批准号:
    512537-2017
  • 财政年份:
    2017
  • 资助金额:
    $ 17.79万
  • 项目类别:
    University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
  • 批准号:
    1404605
  • 财政年份:
    2014
  • 资助金额:
    $ 17.79万
  • 项目类别:
    Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
  • 批准号:
    1263713
  • 财政年份:
    2013
  • 资助金额:
    $ 17.79万
  • 项目类别:
    Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
  • 批准号:
    425749-2012
  • 财政年份:
    2012
  • 资助金额:
    $ 17.79万
  • 项目类别:
    Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
  • 批准号:
    1159886
  • 财政年份:
    2012
  • 资助金额:
    $ 17.79万
  • 项目类别:
    Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
  • 批准号:
    19560760
  • 财政年份:
    2007
  • 资助金额:
    $ 17.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
  • 批准号:
    234753-2000
  • 财政年份:
    2003
  • 资助金额:
    $ 17.79万
  • 项目类别:
    Collaborative Research and Development Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了